EGFR and non-small cell lung carcinoma: Although both afatinib and osimertinib have demonstrated clinical activity in treatment-naive non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor (EGFR) mutations, the efficacy and safety of afatinib after progression on osimertinib remain unclear.